An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited announced its participation in the TD Cowen Annual Healthcare Conference in Boston, where CEO Riccardo Canevari will present the company’s investment proposition. This presentation is a strategic move to attract investor interest, showcasing Radiopharm’s world-class pipeline and potential market leadership in radiopharmaceuticals, particularly in areas with high unmet medical needs.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company focused on developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications. It has a deep pipeline of differentiated molecules including peptides, small molecules, and monoclonal antibodies, targeting cancers such as brain, lung, breast, and pancreas, and is listed on the ASX since November 2021.
YTD Price Performance: 20.0%
Average Trading Volume: 10,226,675
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$56.02M
See more data about RAD stock on TipRanks’ Stock Analysis page.